Developing Innovative Treatments for Neurological and Kidney Diseases

Learn more about Diamedica

About Diamedica

DiaMedica (TSX-V:DMA; OTCQB:DMCAF) is a biopharmaceutical company focused on developing innovative treatments for neurological and kidney diseases where no current therapies are available.

About Diamedica
Learn more about Diamedica

Product Candidates

DiaMedica’s lead clinical stage product, DM199, is a recombinant human tissue kallikrien (rhKLK-1) protein to treat acute ischemic stroke and diabetic kidney disease.

Investors

Investors

-- DMA
-- TSX Venture Exchange
--
-- DMCAF
-- OTCQB
--
View Investor Relations ›